OXILIO LIMITED
OXILIO LIMITED is a London-based clinical-stage pharmaceutical company that repurposes and reformulates off-patent drugs for oncology indications, advancing candidates OXL001 and OXL002 through outsourced CMC and clinical development toward licensing-based commercialisation.
- Company typePrivate
- Founded2019
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What OXILIO LIMITED does
Oxilio Limited is a London-based, privately held pharmaceutical drug development company founded in 2019 that operates a platform-based approach centred on identifying, reformulating, and commercialising off-patent drugs for new oncology indications. Its core services comprise drug repurposing (leveraging existing registration and post-marketing real-world safety data to reduce development risk), novel formulation development (enhancing bioavailability, reducing pill burden, and generating new intellectual property around off-patent molecules), and "Gold Standard Modelling and Simulation" (in-silico optimisation of dose and dosing regimen to inform clinical trial design and regulatory decision-making). The company currently lists two drug candidates in its pipeline — OXL001, for which it secured UK MHRA/REC approval in September 2022 and completed a first clinical trial in June 2023, and OXL002, a parallel reformulation candidate — both based on previously approved drugs being re-engineered for cancer therapy.
The business model is presently pre-commercial: Oxilio has no marketed products, pricing is not applicable, and revenue figures are not disclosed. Anticipated income streams include one-time licensing transactions and ongoing royalty arrangements with development and commercialisation partners, alongside licence agreements already established with TRx Biosciences Limited (October 2021) and Nuformix plc (September 2021, with the exclusive option exercised in March 2021). CMC and clinical manufacturing execution is outsourced to contract partners such as Quotient Sciences. IP is being actively consolidated, including the September 2023 acquisition of Nuformix plc patents and the March 2022 acquisition of LSHS Consulting Ltd. for IP and drug development expertise. The company is led by Co-CEOs Ralph Browning (finance and capital markets background at Deutsche Bank, MasterCard International, NatWest, and ICI) and Dr Simon Yaxley (Oxford-trained neuroscientist who previously founded Premier Research and scaled it to 1,400+ drug development professionals across 26 countries), operates with 1–10 employees from its registered office at 86-90 Paul Street, London, and recently incorporated a wholly-owned subsidiary, Biovara Ltd., in April 2025 to house a distinct line of business.
OXILIO LIMITED firmographics
Firmographics- Name
- OXILIO LIMITED
- Legal name
- OXILIO LIMITED
- Website
- https://oxilio.co.uk
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OXILIO LIMITED is a London-based clinical-stage pharmaceutical company that repurposes and reformulates off-patent drugs for oncology indications, advancing candidates OXL001 and OXL002 through outsourced CMC and clinical development toward licensing-based commercialisation.
- Ownership category
- akta.pro rank
OXILIO LIMITED industry classification
Industry- Product category
- Oncology Drug Development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)
Keywords
Where OXILIO LIMITED is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
OXILIO LIMITED business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug Commercialisation: Revenue generated from bringing repurposed cancer drugs to market through regulatory approval and commercial launch
- Licensing and Royalty Agreements: Licence agreements with partners such as TRx Biosciences Limited and Nuformix plc generating licensing revenue
Distribution channels1 record
Marketing channels2 records
OXILIO LIMITED product offering
Product offeringCore offering
Oxilio is a clinical-stage pharmaceutical company that identifies, repurposes and reformulates existing approved drugs for new oncology indications. Its pipeline includes two drug candidates, OXL001 and OXL002, both based on off-patent drugs being reformulated for cancer therapy with enhanced bioavailability and reduced pill burden. The company leverages its Gold Standard Modelling and Simulation platform to optimize dosing and formulation in-silico, accelerating clinical development and reducing time, cost and risk relative to de novo drug development.
Product overview
Oxilio is a pharmaceutical drug development company operating a platform-based approach centered on drug repurposing and reformulation for cancer therapy. The company leverages three core services: Drug Repurposing (identifying new uses for existing approved drugs), Reformulation (optimizing bioavailability and dosing through novel formulations), and Gold Standard Modelling and Simulation (computational optimization of dosing regimens). The current drug development pipeline centers on two named drug candidates—OXL001 and OXL002—both based on off-patent drugs being reformulated for enhanced cancer treatment outcomes. This approach enables the company to reduce development risk, cost, and time-to-market by building on existing safety and efficacy data.
Differentiator
Problem solved
Functional benefit
Products and services
- OXL001 Repurposed and reformulated drug candidate based on an off-patent drug previously approved for a different indication; undergoing novel formulation development to enhance performance, reduce production costs and target cancer treatment.
- OXL002 Reformulation drug candidate based on an off-patent drug previously approved for a different indication; undergoing formulation development to enhance bioavailability, reduce pill burden and improve patient compliance in cancer therapy.
- Drug Repurposing Services Identification and development of existing approved drugs for new therapeutic indications in cancer treatment, leveraging substantial existing safety and efficacy data to reduce development cost, time and risk.
- Reformulation Services Enhancing drug bioavailability and optimising dose through novel formulation development, aimed at improving patient compliance through reduced pill burden and generating intellectual property opportunities.
- Gold Standard Modelling and Simulation In-silico optimisation of dose and dosing regimen using advanced modelling and simulation techniques to inform clinical trial design and facilitate regulatory decision-making.
Quantifiable outcome
- Significant reduction in development cost compared to de novo drug development
- +2 more outcomes
Companies that use OXILIO LIMITED
Customer profileSegments1 record
Ideal customer profiles2 records
OXILIO LIMITED technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
OXILIO LIMITED partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- CMS EquIP ProgrammeminorAccepted into CMS EquIP programme in April 2024, providing access to expertise and support services
- Quotient SciencescoreOXL001 formulation optimisation and clinical trial preparation contract. Cocrystal formulation optimisation work commissioned. Development partner for clinical manufacturing
- TRx Biosciences LimitedcoreLicence agreement established with TRx Biosciences Limited for development activities related to Oxilio's drug pipeline including clinical evaluation of OXL001 novel formulation
- Nuformix plccoreLicence agreement and exclusive option agreement for drug repurposing technologies. Acquired Nuformix plc patents in September 2023. Exercise of exclusive option agreement in March 2021
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
OXILIO LIMITED competitors and assessment
Company assessmentDirect peers
- Nuformix plc: UK-listed pharmaceutical company specializing in cocrystal and formulation technologies to repurpose existing APIs for new indications. Oxilio's existing licensing partner; uses similar novel-formulation IP approaches on off-patent drugs.
- Lantern Pharma: US clinical-stage oncology company using AI-driven drug development and repurposing to advance cancer candidates. Comparable in scale and clinical-stage model, with similar pipeline-of-candidates approach.
- Pharnext: France-based clinical-stage pharma applying drug repurposing to develop combination therapies for neurological and rare diseases. Operates the same 'repurposing-first' development model targeting underserved therapeutic areas.
- Redx Pharma: UK-based clinical-stage pharma focused on developing repurposed and novel small-molecule drugs for oncology and fibrotic disease. Directly comparable as a small-cap oncology drug developer using reformulation/repurposing strategies.
Emerging players
- Moleculin Biotech: US clinical-stage biotech developing repurposed and reformulated oncology candidates with small headcount and clinical-trial-stage assets. Comparable scale and pipeline structure to Oxilio.
- TRx Biosciences Limited: UK-based pharmaceutical developer focused on novel formulations of established drugs; Oxilio's existing clinical evaluation partner for OXL001. Operates in adjacent formulation/repurposing space.
- Biovista Inc. Drug repurposing company using AI to identify new indications for existing molecules, with oncology and CNS focus. Smaller peer pursuing the same strategy of using computational methods to expand the use of approved drugs.
Others
- Premier Research: Global CRO focused on oncology, CNS, and pain clinical development — founded by Oxilio co-CEO Dr. Simon Yaxley. Comparable in therapeutic focus and clinical service capability, though Premier is a CRO rather than a sponsor.
- Quotient Sciences: UK-based drug development CDMO providing formulation optimization and clinical manufacturing services; existing partner of Oxilio for OXL001. Not a competitor but an adjacent infrastructure provider critical to Oxilio's pipeline.
Broad incumbents
- Aprea Therapeutics: Clinical-stage oncology company developing small-molecule therapeutics, including candidates with reformulation strategies. Broader oncology biotech with a comparable pipeline-development approach and clinical-stage profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
OXILIO LIMITED social profiles
Digital presenceOXILIO LIMITED financial estimates
Financial estimateRevenue estimate
Valuation estimate
OXILIO LIMITED leadership team
Management profileNumber of profiles
Profiles2 records
OXILIO LIMITED subsidiaries and ownership
Company hierarchySubsidiaries1 record
OXILIO LIMITED funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OXILIO LIMITED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OXILIO LIMITED
What does OXILIO LIMITED do?
Oxilio is a clinical-stage pharmaceutical company that identifies, repurposes and reformulates existing approved drugs for new oncology indications. Its pipeline includes two drug candidates, OXL001 and OXL002, both based on off-patent drugs being reformulated for cancer therapy with enhanced bioavailability and reduced pill burden. The company leverages its Gold Standard Modelling and Simulation platform to optimize dosing and formulation in-silico, accelerating clinical development and reducing time, cost and risk relative to de novo drug development.
Is OXILIO LIMITED a public or private company?
OXILIO LIMITED is a private company. It is classified as venture growth investor backed and is currently operating.
When was OXILIO LIMITED founded?
OXILIO LIMITED was founded in 2019. It employs 1 to 10 people.
Where is OXILIO LIMITED based?
OXILIO LIMITED is headquartered in London, United Kingdom, in the Europe region.
How does OXILIO LIMITED make money?
Two revenue lines are on record. Drug Commercialisation is the primary driver. The others are licensing and Royalty Agreements.
Who are OXILIO LIMITED's main competitors?
Direct peers on record are Nuformix plc, Lantern Pharma, Pharnext and Redx Pharma. Emerging players are Moleculin Biotech, TRx Biosciences Limited and Biovista Inc.. Others are Premier Research and Quotient Sciences. Aprea Therapeutics is listed as a broad incumbent.
Does OXILIO LIMITED have an API?
No public API is recorded for OXILIO LIMITED.
What industry is OXILIO LIMITED in?
OXILIO LIMITED's product category is Oncology Drug Development. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 325412 and its SIC code is 2834.